CanaQuest President Interviewed by the Wall Street Analyzer
The attached is the transcript of an interview conducted by the Wall Street Analyzer with Paul Ramsay, President of CanaQuest Medical Corp. and posted on the Wall Street Analyzer’s website on January 5, 2023. Additionally, the full interview can be listened to on the Wall Street Analyzer’s website - Canaquest Medical Corp (OTC: CANQF) | The Wall Street Analyzer
1. Can you discuss the impact of the company's recent news developments.
We recently announced a Statistically Significant Reduction of Seizures for Epilepsy Compared to Standard CBD from a Clinical Dose & Efficacy Study ('Study'') conducted by Dr. W McIntyre Burnham, with the Ontario Brain Institute and emeritus professor of the University of Toronto's Temerty Faculty of Medicine. In comparison to standard CBD, CQ-001 demonstrated 40% more seizure reduction at a medium dose in the maximal electroshock seizure (MES) model.
These results set the stage for substantially smaller dosages of CBD generating the desired results without the negative side effects and will define a dosage of CQ-001 for a clinical trial (Phase 11/111, double-blind trial, 60 patients).
We have identified the regulatory pathways to obtain Rx Drug Identification Numbers (DINs) in Canada and the USA for Epilepsy rare neurological conditions. CQ- 001, in combination with its proprietary processing and delivery method, is estimated to be approved in about 3 years.